Image
Live Meeting Series

PrEParing to End the Epidemic

Optimizing HIV Prevention in Primary Care

Meeting Slides

Patient Poster

Clinical Practice Guidelines

Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update). A clinical practice guideline.

US Public Health Service. Centers for Disease Control and Prevention; 2021.

Sexually transmitted infections treatment guidelines. 2021.

Centers for Disease Control and Prevention. Last reviewed July 2021.

2018 quick reference guide: recommended laboratory HIV testing algorithm for serum or plasma specimens.

CDC Stacks. Centers for Disease Control and Prevention; last updated January 2018.

Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV—United States, 2016. 

CDC Stacks. Centers for Disease Control and Prevention; last updated May 2018.

HIV pre-exposure prophylaxis in the EU/EEA and the UK: implementation, standards and monitoring: technical guidance.

European Centre for Disease Prevention and Control (ECDC). 2021.

The Fenway Guide to Lesbian, Gay, Bisexual, and Transgender Health.

Makadon H, et al, American College of Physicians (ACP), eds. 2nd ed. Boston, MA: Fenway Health; 2015.

Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society—USA Panel.

Saag MS, et al. JAMA. 2020;324(16):1651-1669.

Professional Organizations & Resources

American Academy of HIV Medicine.

Basic statistics.

Centers for Disease Control and Prevention; updated April 2022.

National Clinician Consultation Center.

University of California, San Francisco; 2020.

HIV drug interactions.

University of Liverpool (website); updated April 2022.

Suggested Readings

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.   

Baeten JM, et al. N Engl J Med. 2012;367(5):399-410.

Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.

Choopanya K, et al. Lancet. 2013;381(9883):2083-2090.

Emtricitabine/tenofovir alafenamide.

HIV.gov. Drug database.

Emtricitabine/tenofovir disoproxil fumarate.

HIV.gov. Drug database.  

Cabotegravir.

HIV.gov. Drug database.

Being PrEPared—preexposure prophylaxis and HIV disparities.

Goldstein RH, et al. N Engl J Med. 2018;379(14):1293-1295.

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Grant RM, et al. N Engl J Med. 2010;363(27):2587-2599.

Lifetime risk of a diagnosis of HIV infection in the United States.

Hess KL, et al. Ann Epidemiol. 2017;27(4):238-243.

Cabotegravir for HIV prevention in cisgender men and transgender women.

Landovitz RJ, et al. N Engl J Med. 2021;385(7):595-608.

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

Mayer KH, et al. Lancet. 2020;396(10246):239-254.

Clinical Commissioning Policy. Reimbursement for the use of generic drugs for pre exposure prophylaxis (PrEP) for the prevention of HIV.

National Health Service. 2020.

How to incorporate HIV PrEP into your practice.

Stewart J, Stekler JD. J Fam Pract. 2019;68(5):254-261.

Patient and Provider assistance: PleasePrEPMe.org

Information about PrEP, nPEP, insurance and insurance rights, finding a PrEP/nPEP provider, and a list of PrEP resources by state

Provider assistance: AETC; AIDS Education & Training Center Program: National Coordinating Resource Center

Supports national HIV priorities by providing training, consultation, and resources

Ready, Set, PrEP! provides free PrEP HIV-prevention medication

Clinic visits and lab tests vary depending on income

If PrEP medication is a good option for your clients, they can choose the application process that is most convenient

By phone: 855-447-8410

Patient assistance (without insurance)

The PrEP patient assistance program will provide medication at no cost for those who meet income guidelines

Uninsured 24/7 support online, by phone during business hours and fax enrollment

Copay assistance (for patients with nongovernment insurance)

Phone number: 1-877-505-6986

Copay assistance/out-of-pocket costs

ViiV Connect

Relevant Resources

Clinical Updates in Systemic Lupus Erythematosus

Improved Diagnostic and Management Strategies

Advances in Immunosupressive Therapy for Solid Organ Transplantation

Long-Term Management Strategies to Improve Patient Outcomes

Acute Management of Migraine Attacks

Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes

Clinical Updates on the Management of Gout

Evidence-Based Strategies for Improved Patient Outcomes

Opioid-Induced Constipation

Proactive Diagnosis and Targeted Management

Chronic Obstructive Pulmonary Disease, Asthma, or Both

Differential Diagnosis and Comprehensive Management Strategies

Improving Outcomes in Chronic Obstructive Pulmonary Disease

Optimizing Maintenance Therapy Across Healthcare Settings

Managing Gout in Primary Care

Evolving Strategies for Diagnosis and Long-Term Management

Clinical Issues in Chronic Pain

Consensus and Controversies for Responsible Opioid Prescribing

Noninsulin Approaches to Managing Type 2 Diabetes

Best Practices in Combination Therapy

Hitting the Target in Type 2 Diabetes

Evolving Approaches to Insulin Based Therapy

Improving Outcomes in Rheumatoid Arthritis

Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms

Clearing the Air

Improving Outcomes for Patients with COPD

Clinical Updates in Type 2 Diabetes

New Strategies for Insulin Replacement Therapy

How Low Do You Go?

Clinical Updates in LDL-C Management

Incretin-Based Therapies For Type 2 Diabetes

Improving Comprehensive Patient Care

Improving Outcomes in Non–24-Hour Sleep-Wake Disorder

Identifying Patients and Tailoring Therapy

Comprehensive Management of Chronic Obstructive Pulmonary Disease

Collaborative Approaches to Guideline-Concordant Patient Care

Clinical Updates in the Management of Severe Asthma

New Strategies for Individualizing Long-term Care

Comprehensive Chronic Pain Management

A Focus on Patients With Opioid-Induced Constipation

Clinical Issues in Bipolar Depression

Consensus and Controversies Across the Spectrum of Patient Presentations

Clinical Updates in Rheumatoid Arthritis

Evolving Treatment Algorithms and Expert Perspectives on Biosimilars

Going Deeper on Atopic Dermatitis

Pathophysiology to the Management of Moderate-to-Severe Disease

Caring for Patients with Severe Asthma

Evolving Best Practices to Optimize Outcomes

PrEP for Your Patients’ Needs

The PCPs Role in Preventing HIV

Looking Beneath The Surface In Atopic Dermatitis

Targeting Immune Dysregulation and Delivering Comprehensive Care

Can You Spot Axial Spondyloarthritis?

The PCP’s Role in Timely Recognition and Referral

Value-Based HIV Formularies

Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care

Evolving Treatment Paradigms For Rheumatoid Arthritis

Translating Comprehensive Patient Evaluations Into Personalized Therapy

Hepatitis C is Curable

Got it? Treat it!

Clinical Updates in Rheumatoid Arthritis

New Perspectives on Targeting Remission and Individualizing Therapy

Real-World Issues in HIV Prevention & Treatment

The Critical Role of the Community Pharmacist

A Better Look at Rheumatoid Arthritis

Using Imaging to Improve Patient Outcomes

BLOCK HIV/HCV

Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.

Evolving Models of HIV Care

Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box

Clinical Issues in Rheumatoid Arthritis

Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs

Advancing the Care of Severe Asthma

Differential Diagnosis, Multidisciplinary Management, and Patient Engagement

Updates in HCV Screening and Treatment

Key Issues Impacting OB/GYN Practice

Pathways to Better Outcomes in Systemic Lupus Erythematosus

Translating Pathophysiology into Targeted Treatments

The Big Picture of IBD

An Interactive Experience Highlighting Recent Clinical Advances

Clinical Issues in Chronic Liver Disease

Hot Topics in HBV, HCV, and NASH

Evolving Models of HIV Care

Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice

Clinical Issues in Rheumatoid Arthritis

Debates & Discussions on the Evolving Role of JAK Inhibitors

Assessing Your Patients for HCV and HIV

Why It Matters in OB/GYN Practice Today

Clearing the Air in Severe Asthma Management

Improving Patient Outcomes Through Shared Clinical Decision Making

HIV as a Chronic Disease

A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities

The Pursuit of Hepatitis C Elimination

How the Pharmacist Can Make a Difference

GLP-1 Receptors Agonists in Type 2 Diabetes

Mechanistic Insights and Evolving Treatment Options

Clinical Issues in Rheumatoid Arthritis

The Evolving Role of JAK Inhibitors

Trends in Infectious Diseases: Updates on Treatment & Prevention Strategies for HIV and HCV

Understanding the Growing Syndemic — Opioids, HCV, and HIV

JAKi in RA Practice

Unpacking the Evidence for Their Use Today and Tomorrow

Airing It Out

A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis

COPD in Managed Care

The Clinical and Utilization Benefits of Exacerbation Prevention

Assimilating the Evidence in T2DM

Cardiovascular and Renal Outcomes With SGLT2 Inhibitors

Demystifying New Evidence for COPD Management

Best Practices for Primary Care

Finding Relief in Osteoarthritis

New Paths to Chronic Pain Management

Stepping Up to the Challenge

The PCP’s Role in HCV Elimination

The Changing Landscape of HIV Prevention

What the Pharmacist Needs to Know about PrEP

Evolving Models of HIV Care (Volume 3)

The Rapid ART Standard of Care: From Evidence to Healthcare Equity

What’s New in Systemic Lupus Erythematosus?

Unlocking Novel Paths to Patient Care

HIV Updates for Pharmacy Practice

Maximizing Your Role to Impact Patient Outcomes

BRIDGE HCV

Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV

Case Challenges in HIV Medicine

Benefits, Barriers, & Best Practices in an Advancing Field

Challenges and Opportunities in HIV

Practical Solutions Across the Spectrum of Care

Expanding HIV Prevention in Colorado—and Nationwide

A PEP/PrEP Training Guide for Pharmacists

Expert Views on the Changing Landscape in RA

The Increasing Role of JAK Inhibitors

Updates in Systemic Lupus Erythematosus

Unlocking Novel Paths to Patient Care

Swimming Upstream in Severe Asthma

New Pathways to Patient Management

Optimizing Advanced Therapies in Ulcerative Colitis: Is Your Practice Up to Date?

A Focus on Clinical Evidence and Guideline Recommendations

COPD Cases & Conversations

Preventing COPD Exacerbations to Improve Outcomes

Treating Hepatitis C in the Primary Care Setting

A Critical Step Toward HCV Elimination

Honing Clinical Skills in HIV Treatment

Considering the Patient, the Provider, and the Science

Hot Topics in HCV

A Multidisciplinary Online Mini-Curriculum

Comprehensive Management in COPD

A Whole Patient Case Series

Clinical Issues in COVID-19

Debates and Discussions about Monoclonal Antibody Therapies

Minimizing Patient Risks From COVID-19

An Update on Monoclonal Antibody Therapies

Cause for Alarm

New Avenues to the Management of Severe Asthma

Maybe It’s NOT Mechanical Back Pain

Getting on the Fast Track to Identify AxSpA

Treating Hepatitis C in the Primary Care Setting

Establishing Clinical Readiness Through Mentored Learning

Finding the Path in Eosinophilic Esophagitis

Interdisciplinary Strategies for Adult and Pediatric Patients

Answering the Call

Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema

Getting Low in Familial Hypercholesterolemia

Reducing LDL-C and a Lifetime of Cardiovascular Risk

Expert Consult Series in Multiple Sclerosis

Updates, Clinical Scenarios, and Future Directions

Putting a Spotlight on Systemic Mastocytosis

A Multidisciplinary Look at Early Diagnosis and Management

Targeting Clear Horizons

Finding the Path in Chronic Rhinosinusitis with Nasal Polyps

Clinical Updates in COVID-19

Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment

Is It Systemic Mastocytosis?

Best Practices for Diagnosis and Management

Monoclonal Antibodies for COVID-19

An Update on Best Practices

Monoclonal Antibodies for COVID-19

New Avenues to Pre-Exposure Prophylaxis

Early Cancer Detection in Primary Care:

Are You Aware of New Blood-Based Multi-Cancer Screening Tools

Choosing Your Path in Systemic Lupus Erythematosus

From Patient Evaluations to New Targeted Therapies

Virologic Failure in HIV

An Updated Clinician’s Guide to Assessment and Management

Applying HIV Advances in Practice

What the Pharmacist Needs to Know

Buffing Up on New and Emerging ART

A Look at the Changing HIV Playing Field

Pharmacy PrEP Education

A “How To” Series Spanning Policy to Practice

BRIDGE PrEP

Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention

Flexing Your Early Cancer Detection Muscles

Strengthening Your Knowledge of Blood-Based Screening Tools

Long-Acting Injectable PrEP:

Bringing HIV Prevention to a New Level

Multi-Cancer Early Detection in Primary Care

What You Need to Know About New Blood-Based Screening Tools

A Call to Action

Monoclonal Antibodies for the Prevention and Treatment of COVID-19

Anemia in Chronic Kidney Disease

New Avenues to Improve Patient Outcomes

What’s the Latest on COVID-19?

Current Prevention and Treatment Strategies

What’s Next

Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis